rare neurological diseases
Ipsen’s cabozantinib accepted by SMC for adults with advanced neuroendocrine tumours
NETs affect approximately seven per 100,000 people in Scotland
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Ipsen appoints Michelle Werner as Executive Vice President, President of North America
Werner previously held senior roles at Bristol Myers Squibb, AstraZeneca and Novartis
Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations
Lefranc has served at Ipsen since 2013, most recently as Senior Vice President
Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn
The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials
Ipsen’s tumour treatment receives MHRA marketing authorisation
This is the first approval in the UK for previously treated advanced neuroendocrine tumours
Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours
Treatment options following disease progression have previously been limited for many patients
Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours
The number of patients newly diagnosed with NETs is believed to be on the rise
Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis
The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease
Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis
The life-long condition affects approximately 1,900 people in Scotland
Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager
The candidate targets a tumour antigen that is highly expressed across several cancer types